Overall, our findings expand the oncogenic signaling network of ALK, and coinhibition of ALK and TOPK may offer a novel strategy for the treatment of ALK-positive NSCLC patients to delay drug resistance. This evidence concerns the gene ALK and non-small cell lung carcinoma.